A model for the long-term planning of physician workforce in Hungary
1Semmelweis University, Faculty of Health Sciences, Institute of Public Health Medicine, Budapest, Hungary.
Abstract:
A computer programme for the long term (25 years) projection of the physician workforce was developed. The input variables were the admittance rate of the medical schools and the unemployment rate of the active physicians, the output variables were the number of active physicians. The age and sex structure, the retirement age were taken into account. Different scenarios were made to compare the impact of the output of medical faculties and the unemployment rate of doctors on the number of active of the physicians in five years intervals for a twenty-five years period. The input of the young graduates varied between 800-600/year, the unemployment rate between 4.5% and nil. At end of the 25 years projection period the reduction of physicians was between 9.6 and 25.0%. The aim was to find a professionally acceptable, socially tolerable and politically eligible optimal relationship among the three variables.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Three-Compartment Open Model
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions


